VANGUARD GROUP INC 13D and 13G filings for Celldex Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-26 5:16 pm Sale | 2026-03-13 | 13G | CELLDEX THERAPEUTICS INC C CLDX | VANGUARD GROUP INC | 0 0.000% | -3,046,331 (Position Closed) | Filing |
| 2024-02-13 5:00 pm Purchase | 2023-12-29 | 13G | CELLDEX THERAPEUTICS INC C CLDX | VANGUARD GROUP INC | 3,046,331 5.570% | 532,767 (+21.20%) | Filing |
| 2023-02-09 11:12 am Purchase | 2022-12-30 | 13G | CELLDEX THERAPEUTICS INC C CLDX | VANGUARD GROUP INC | 2,513,564 5.340% | 100,508 (+4.17%) | Filing |
| 2022-02-09 3:33 pm Sale | 2021-12-31 | 13G | CELLDEX THERAPEUTICS INC C CLDX | VANGUARD GROUP INC | 2,413,056 5.170% | -3,848,847 (-61.46%) | Filing |